nuclear
receptor
heterodim
liver
x
receptor
lxr
recent
identifi
key
transcript
regul
gene
involv
lipid
homeostasi
inflamm
lxr
ligand
neg
regul
macrophag
inflammatori
gene
express
multipl
sclerosi
ms
demyelin
diseas
central
nervou
system
unknown
caus
character
recurr
inflamm
involv
macrophag
inflammatori
mediat
sweden
belong
countri
high
ms
incid
itali
incid
lower
except
sardinia
incid
even
higher
sweden
subject
sardinia
ethnic
homogen
differ
swede
also
regard
genet
background
environ
studi
lxr
relat
molecul
blood
mononuclear
cell
mnc
femal
patient
untreat
relapsingremit
ms
sassari
sardinia
stockholm
sweden
sexand
agematch
healthi
control
hc
area
mrna
express
evalu
realtim
pcr
lxra
lower
p
ms
mean
ae
sem
ae
n
compar
hc
ae
n
lxra
lower
ms
stockholm
ae
n
compar
correspond
hc
ae
n
p
compar
ms
ae
n
p
hc
ae
n
p
sardinia
ms
patient
stockholm
sassari
also
express
lower
p
lxrb
ae
compar
correspond
hc
ae
ms
stockholm
associ
higher
ae
versu
ae
p
higher
estrogen
receptorbcx
ae
versu
ae
p
compar
correspond
hc
hc
sassari
higher
androgen
receptor
ae
compar
ms
sassari
ae
p
ms
ae
p
hc
stockholm
ae
p
ms
sassari
lower
compar
correspond
hc
ae
versu
ae
p
lower
prostaglandin
ae
compar
hc
ae
p
ms
ae
p
hc
stockholm
ae
p
find
identifi
lxr
relat
molecul
involv
ms
stockholm
sassari
sex
hormon
receptor
seem
involv
ms
sassari
multipl
sclerosi
ifnb
induc
dendrit
cell
produc
enhanc
type
interferon
product
huang
adikari
u
sanna
g
alm
dc
antigen
bdca
investig
abil
produc
type
ifn
respons
viru
stimul
show
ifnb
induc
develop
dc
human
blood
monocyt
coexpress
neg
specif
marker
plasmacytoid
dc
ifnbmodul
dc
produc
larg
amount
enhanc
ifnb
ifnb
product
find
indic
ifnbmodul
dc
repres
myeloid
dc
subset
diminish
express
potent
function
lack
antivir
capac
associ
psoriasi
throat
infect
streptococcu
pyogen
suggest
potenti
antigen
target
cell
known
infiltr
dermi
epidermi
psoriat
skin
streptococc
protein
share
extens
sequenc
homolog
human
epiderm
keratin
keratin
mostli
absent
uninvolv
skin
upregul
psoriat
lesion
increas
evid
cell
play
import
effector
role
psoriasi
proteinprim
cell
may
recogn
share
epitop
skin
via
molecular
mimicri
identifi
candid
epitop
peptid
sequenc
select
basi
predict
bind
sequenc
similar
protein
match
peptid
sequenc
protein
set
peptid
poor
predict
bind
also
select
individu
psoriasi
healthi
control
famili
histori
psoriasi
recruit
pbmc
incub
peptid
antigen
tcell
activ
later
skinhom
cutan
lymphocyteassoci
antigen
cla
express
subset
cell
evalu
express
intracellular
ifng
accumul
use
flow
cytometri
demonstr
psoriasi
patient
signific
tcell
ifng
respons
peptid
protein
select
basi
sequenc
homolog
predict
hlacw
bind
respons
time
frequent
skinhom
cutan
lymphocyteassoci
antigenexpress
cla
subset
cell
cell
show
borderlin
respons
cell
nonpsoriat
individu
respond
peptid
rare
peptid
also
appli
cla
subset
find
indic
psoriat
individu
cell
recogn
keratin
selfantigen
epitop
share
streptococc
protein
human
keratin
may
target
cell
infiltr
psoriat
skin
lesion
autoantibodi
direct
citrullinecontain
protein
impress
specif
nearli
ra
patient
suggest
involv
pathogenesi
target
epitop
gener
posttransl
modif
catalys
calciumdepend
enzym
peptidyl
arginin
deaminas
convert
posit
charg
arginin
polar
uncharg
citrullin
aim
studi
analys
presenc
citrullin
joint
differ
time
point
collageninduc
arthriti
da
rat
immunohistochemistri
investig
immunogen
arthritogen
affect
citrullin
rat
serum
albumin
rsa
collagen
type
ii
cii
result
indic
citrullin
could
detect
joint
arthrit
anim
first
appear
onset
diseas
increas
diseas
progress
chronic
state
unimmun
anim
time
point
clinic
sign
arthriti
neg
morpholog
state
infiltr
macrophag
well
cartilag
surfac
stain
posit
citrullin
major
sourc
citrullin
protein
appear
fibrin
deposit
specif
citrsa
tcell
respons
observ
anim
challeng
citrullin
rsa
respons
record
rsa
use
stimulu
igg
analysi
reveal
respons
toward
modifi
protein
also
crossreact
nativ
rsa
tcell
bcell
respons
note
anim
inject
unmodifi
rsa
citcii
induc
diseas
higher
incid
earlier
onset
nativ
counterpart
conclud
contrast
human
diseas
citrullin
seem
appear
clinic
sign
inflamm
proce
citrullin
detect
specif
joint
organ
investig
neg
also
conclud
citrullin
protein
break
toler
increas
arthritogen
properti
ectop
germin
center
gc
detect
salivari
gland
approxim
patient
syndrom
ss
appear
primari
secondari
ss
previous
ectop
gc
associ
increas
local
autoantibodi
product
aim
studi
determin
whether
gc
primari
syndrom
pss
defin
distinct
seroimmunolog
phenotyp
retrospect
materi
haematoxylin
eosinstain
paraffinembed
tissu
section
minor
salivari
gland
tissu
patient
pss
morpholog
screen
presenc
ectop
gc
gclike
lesion
detect
pss
patient
seventytwo
pss
patient
lack
structur
gc
randomli
select
comparison
focu
score
significantli
increas
gc
patient
compar
gcpatient
p
gc
group
patient
present
antirossa
compar
gcgroup
antilassb
detect
gc
patient
compar
gcpatient
sixtyon
percentag
gc
patient
present
increas
level
igg
nonsignific
differ
compar
gcpatient
p
level
rf
ana
ena
igm
iga
similar
patient
group
esr
crp
conclus
patient
ectop
gc
higher
focu
score
often
present
autoantibodi
increas
level
igg
compar
pss
patient
regular
focal
infiltr
gc
find
may
indic
certain
seroimmunolog
phenotyp
warrant
prospect
studi
associ
mannosebind
lectin
vascular
complic
type
diabet
complement
activ
inflamm
suggest
pathogenesi
diabet
vascular
lesion
investig
serum
mannosebind
lectin
mbl
level
polymorph
mbl
gene
type
diabet
patient
without
diabet
nephropathi
associ
macrovascular
complic
polymorph
mbl
gene
serum
mbl
level
determin
patient
overt
nephropathi
patient
persist
normoalbuminuria
match
age
sex
durat
diabet
well
healthi
control
subject
frequenc
high
low
express
mbl
genotyp
similar
patient
healthi
control
high
mbl
genotyp
significantli
frequent
diabet
patient
nephropathi
normoalbuminur
group
risk
nephropathi
given
high
mbl
genotyp
assess
odd
ratio
p
median
serum
mbl
concentr
significantli
higher
patient
nephropathi
patient
normoalbuminuria
mgl
iqr
mgl
versu
mgl
iqr
p
even
compar
patient
ident
genotyp
serum
mbl
level
higher
nephropathi
group
normoalbuminur
group
patient
histori
cardiovascular
diseas
significantli
elev
mbl
level
independ
nephropathi
statu
mgl
iqr
mgl
versu
mgl
iqr
mgl
p
differ
mbl
level
patient
without
vascular
complic
driven
primarili
pronounc
differ
among
carrier
high
mbl
genotyp
p
find
suggest
mbl
may
involv
pathogenesi
microvascular
macrovascular
complic
type
diabet
determin
mbl
statu
might
use
identifi
patient
increas
risk
develop
complic
neuroimmunolog
unit
center
molecular
medicin
karolinska
institutet
stockholm
sweden
email
juditwef
cmmkise
dna
vaccin
code
encephalitogen
peptid
mog
protect
subsequ
develop
experiment
autoimmun
encephalomyel
eae
protect
associ
type
immun
respons
depend
presenc
cpg
dna
motif
mechan
underli
observ
reduct
eae
develop
protect
rat
fulli
clarifi
investig
immunolog
characterist
lymphocyt
dna
vaccinaton
subsequ
eae
induct
confirm
protect
associ
suppress
cell
transcript
novel
molecul
rat
tcell
immunoglobulinand
mucindomaincontain
molecul
report
exclus
express
differenti
cell
alter
dna
vaccin
note
clonal
delet
upon
toler
detect
antigenspecif
lymphocyt
popul
upregul
ifng
upon
recal
stimul
week
protect
dna
vaccin
protect
rat
observ
alter
antigenspecif
respons
reduc
mhc
ii
express
splenocyt
earli
eae
induct
antigenspecif
upregul
ifnb
upon
recal
stimul
reduc
lymphocyt
thu
demonstr
associ
protect
effect
dna
vaccin
express
ifnb
current
investig
cellular
mechan
behind
ifnbmedi
protect
multipl
sclerosi
ms
autoimmun
condit
character
degener
nerv
fibr
myelin
sheet
candid
autoantigen
myelin
basic
protein
mbp
especi
attract
attent
presenc
antimbp
antibodi
predictor
definit
ms
role
pathogenesi
remain
obscur
cell
long
known
play
pivot
role
pathogenesi
ms
recent
import
role
b
cell
autoantigenpres
cell
demonstr
autoimmun
diseas
includ
rheumatoid
arthriti
diabet
uptak
mbp
b
cell
present
mbpderiv
peptid
helper
th
cell
b
cell
may
promot
format
complement
c
activ
immun
complex
ic
mbp
natur
autoantibodi
healthi
individu
diseaseassoci
antimbp
antibodi
ms
patient
respect
investig
format
mbpcontain
ic
bind
mbp
b
cell
mbpelicit
induct
thcell
bcell
prolifer
cytokin
product
peripher
blood
mononuclear
cell
pbmc
healthi
donor
grown
presenc
intact
cinactiv
serum
healthi
donor
patient
ms
mbp
induc
measur
prolifer
b
cell
cell
observ
product
tnfa
ifng
pbmc
respons
incub
mbp
presenc
sera
healthi
control
well
sera
ms
patient
contrast
product
detect
current
investig
capabl
ms
sera
promot
format
mbpcontain
ic
therebi
enhanc
cytokin
respons
virtu
elev
antimbp
content
phagolysosom
local
acid
sphingomyelinas
asmas
activ
proinflammatori
cytokin
tnf
ifng
gener
signal
molecul
ceramid
turn
result
activ
proteas
like
cathepsin
characterist
asmas
suggest
possibl
role
molecul
phagocytot
uptak
phagosom
degrad
process
antigen
antigen
present
show
asmas
mice
fail
elimin
noncytopath
lymphocyt
choriomening
lcm
viru
rapidli
litterm
wildtyp
mice
investig
immun
respons
reveal
reduc
expans
cell
secret
ifng
respons
contact
target
cell
well
cytolyt
activ
virusspecif
cell
sever
impair
addit
phase
lcm
virusspecif
dth
respons
mediat
cell
consecut
diminish
asmas
mice
howev
secondari
memori
respons
virusspecif
ctl
alter
abstract
viru
effect
control
least
month
asmas
mice
conclus
result
studi
suggest
involv
asmas
activ
expans
matur
virusspecif
cell
acut
infect
mice
lcm
viru
novel
marker
altern
activ
macrophag
macrophag
galactosetyp
ctype
lectin
parallel
dichotomi
macrophag
capabl
develop
function
molecularli
distinct
subpopul
due
differ
exampl
cytokin
environ
patholog
condit
beststudi
classic
activ
macrophag
induc
type
stimuli
ifng
type
ii
cytokin
environ
antagon
classic
activ
macrophag
capabl
altern
activ
macrophag
howev
molecular
marker
associ
type
ii
cytokinedepend
altern
activ
macrophag
remain
scarc
besid
earlier
document
marker
macrophag
mannos
receptor
arginas
recent
demonstr
murin
altern
activ
macrophag
character
increas
express
ym
report
express
two
member
mous
macrophag
galactosetyp
ctype
lectin
gene
famili
term
induc
divers
popul
altern
activ
macrophag
includ
periton
macrophag
elicit
infect
protozoan
trypanosoma
brucei
helminth
taenia
crassicep
alveolar
macrophag
elicit
mous
model
allerg
asthma
also
demonstr
vitro
upregul
express
vivo
induct
depend
receptor
signal
moreov
show
regul
mgl
express
similar
human
monocyt
monocytederiv
macrophag
henc
macrophag
galactosetyp
ctype
lectin
repres
novel
marker
murin
human
altern
activ
macrophag
thu
pave
way
character
phenotyp
macrophag
occur
condit
background
human
parvoviru
ubiquit
pathogen
normal
caus
mild
selflimit
diseas
also
capabl
caus
signific
patholog
longterm
persist
small
size
stabil
viru
make
suitabl
map
full
breath
kinet
cellular
immun
respons
follow
acut
viral
infect
method
five
patient
acut
primari
infect
includ
studi
follow
consecut
week
cellular
immun
respons
map
ifng
enzymelink
immunospot
overlap
peptid
span
whole
genom
result
five
acut
infect
patient
abl
monitor
kinet
strong
specif
cellular
immun
reaction
respons
peak
level
sfc
million
pbmc
roughli
correspond
cell
circul
peripher
blood
week
postinfect
respons
individu
patient
direct
three
four
differ
peptid
pool
specif
confin
epitop
present
pool
throughout
followup
period
major
respons
direct
viru
nonstructur
protein
two
patient
show
respons
capsid
protein
elicit
epitop
case
conclus
cellular
immun
respons
acut
infect
surprisingli
narrow
distribut
remain
high
level
week
postinfect
initi
epitop
specif
maintain
major
respons
target
viru
nonstructur
protein
includ
vaccin
prepar
evalu
infect
relationship
malnutrit
malaria
controversi
one
hand
malaria
may
caus
malnutrit
malnutrit
may
modul
suscept
diseas
investig
associ
plasmodium
falciparum
malaria
malnutrit
cohort
children
live
coast
kenya
studi
involv
longitudin
followup
clinic
malaria
episod
anthropometr
measur
four
crosssect
survey
use
poisson
regress
analysi
investig
associ
malaria
nutrit
statu
compar
baselin
children
waz
haz
score
crude
incid
rate
ratio
irr
malaria
children
low
haz
waz
score
period
prior
assess
ci
respect
suggest
associ
malaria
subsequ
develop
pem
howev
found
age
act
effect
modifi
associ
malaria
malnutrit
irr
malaria
children
year
old
subsequ
character
wast
p
signific
overal
relationship
malaria
lowhaz
found
regress
analysi
adjust
interact
age
irr
p
although
children
live
coast
kenya
continu
suffer
clinic
episod
uncompl
malaria
throughout
first
decad
associ
malaria
malnutrit
appear
limit
first
year
life
astrinidouvakaloudi
xytsa
diamanti
h
ioannidi
p
pangidi
microbiolog
depart
gener
hospit
thessaloniki
agio
pavlo
thessaloniki
greec
nefrolog
nd
ika
hospit
thessaloniki
thessaloniki
greec
email
stasa
holgr
aim
renal
dysfunct
may
influenc
colon
gastric
mucosa
ureasplit
bacteria
helicobact
pylori
increas
urea
concentr
gastric
juic
aim
investig
preval
h
pylori
patient
endstag
renal
diseas
esrd
receiv
longterm
haemodialysi
treatment
method
studi
includ
sera
patient
esrd
male
femal
undergo
period
haemodialysi
mean
time
treatment
month
use
elisa
techniqu
investig
presenc
igg
iga
antibodi
h
pylori
well
igg
caga
antibodi
specif
caga
strain
h
pylori
sera
healthi
blood
donor
use
control
group
result
h
pylori
igg
antibodi
detect
patient
dialysi
group
test
posit
iga
igg
caga
antibodi
present
preval
h
pylori
igg
iga
caga
igg
antibodi
control
group
respect
conclus
although
intern
data
suggest
preval
h
pylori
infect
esrd
patient
healthi
individu
studi
seem
case
higher
blood
gastric
juic
urea
level
may
risk
factor
among
mani
other
studi
requir
order
understand
relat
h
pylori
infect
group
patient
flander
interunivers
institut
biotechnolog
depart
molecular
cellular
interact
free
univers
brussel
brussel
pasteur
institut
brussel
mycobacteri
immunolog
brussel
belgium
email
tgartner
vubacb
immun
tuberculosi
tb
caus
mycobacterium
tuberculosi
depend
larg
activ
mainten
strong
cellmedi
immun
respons
involv
cell
abil
respond
cytokin
particularli
ifng
recent
studi
suggest
bcg
licens
vaccin
tuberculosi
may
fail
induc
tcell
respons
lung
mucosa
may
therefor
protect
pulmonari
tb
decreas
tb
mortal
may
achiev
enhanc
immun
lung
present
studi
evalu
induct
antigenspecif
immun
lung
intranas
deliveri
lipoprotein
opri
pseudomona
aeruginosa
opri
shown
tolllik
receptor
agonist
given
subcutan
induc
immun
respons
heterolog
antigen
fusion
opri
mtb
use
subunit
vaccin
homolog
primeboost
immun
addit
combin
dna
vaccin
dna
bcg
heterolog
primeboost
vaccin
intranas
parenter
deliveri
elicit
compar
tcell
respons
spleen
addit
deliveri
elicit
specif
tcell
respons
lung
lymph
node
lln
intramuscular
deliveri
dna
induc
signific
system
immun
respons
intranas
boost
enhanc
respons
addit
induc
antigenspecif
ifng
respons
lln
opri
may
therefor
effici
adjuv
mucos
boost
continu
evalu
protect
induc
opribas
primeboost
vaccin
pulmonari
tb
result
immunogen
protect
intraven
mtb
infect
present
tolllik
receptor
tlr
pattern
recognit
receptor
innat
immun
system
recogn
molecular
structur
pathogen
cellular
stressassoci
molecul
tlrligand
interact
trigger
activ
inflammatori
signal
transduct
express
gene
involv
host
defens
studi
examin
requir
differ
tlr
adaptor
molecul
virusinduc
chemokin
express
current
tri
identifi
tlr
involv
found
herpesviru
herp
simplex
viru
hsv
paramyxoviru
sendai
viru
requir
function
genom
induc
express
proinflammatori
chemokin
human
murin
monocyt
cell
line
virus
independ
tlr
adaptor
molecul
trif
mal
howev
overexpress
vaccinia
virusencod
inhibitor
tlrsignal
dominantneg
total
inhibit
hsvinduc
rant
express
partial
prevent
sendai
viru
induc
chemokin
suggest
hsvinduc
rant
express
occur
via
tlr
pathway
wherea
sendai
viru
util
tlrdepend
independ
pathway
stimul
express
rant
current
tri
identifi
tlr
involv
data
studi
also
present
meet
oligoadenyl
synthetas
interferoninduc
doublestrand
rnaactiv
antivir
enzym
protein
known
catalys
specif
nucleotidyl
transfer
first
crystal
structur
synthetas
reveal
structur
conserv
specif
poli
polymeras
coupl
structureguid
mutagenesi
support
conserv
catalyt
mechan
specif
nucleotidyl
transferas
comparison
structur
superfamili
member
indic
donor
substrat
bound
conserv
activ
site
featur
acceptor
substrat
orient
nonconserv
region
synthetas
activ
viral
doublestrand
rna
infect
cell
initi
cellular
respons
synthes
oligoadenyl
turn
activ
rnase
l
crystal
structur
suggest
activ
involv
domaindomain
shift
identifi
put
dsrna
activ
site
probe
mutagenesi
demonstr
site
requir
bind
dsrna
subsequ
activ
oa
rnabind
site
differ
known
rnabind
site
rather
form
defin
threedimension
domain
locat
interfac
two
major
domain
oa
novel
architectur
ensur
dsrna
helix
make
simultan
contact
domain
oa
ensur
subsequ
structur
rearrang
lead
activ
oa
work
provid
structur
insight
cellular
recognit
doublestrand
rna
viral
origin
identifi
novel
rnabind
motif
bacteriaspecif
iga
antibodi
effici
opsonin
neutrophil
mononuclear
phagocyt
provid
phagocyt
express
fca
receptor
express
stimul
inflammatori
cytokin
activ
complement
factor
certain
microbi
compon
one
studi
unstimul
phagocyt
abl
ingest
iga
antibodytr
pneumococci
presenc
complement
found
activ
iga
antibodi
along
altern
pathway
pneumococci
produc
proteas
cleav
human
molecul
hing
region
leav
faba
monoval
depriv
fca
contain
dock
site
vastli
predomin
subclass
iga
upper
airway
circul
human
aim
examin
effect
proteas
activ
complement
phagocytosi
iga
antibodyco
pneumococci
unstimul
human
phagocyt
cell
line
materi
method
monoclon
antibodi
serotyp
pneumococc
capsular
polysaccharid
ps
gener
heterohybridoma
techniqu
involv
b
cell
human
vaccine
isogen
serotyp
pneumococci
without
proteas
activ
respect
obtain
inactiv
iga
gene
strain
opsonophagocytosi
quantit
use
assay
describ
romerostein
et
al
base
enumer
surviv
bacteria
cultur
integr
iga
molecul
examin
western
blot
result
antibodi
polysaccharideinduc
phagocytosi
proteasedefici
pneumococci
equal
well
absenc
presenc
complement
antibodi
polysaccharid
display
fourfold
higher
opsonophagocytosi
titer
proteas
defici
compar
homolog
wildtyp
target
bacteria
similar
effect
proteas
activ
target
bacteria
observ
parallel
experi
antibodi
polysaccharid
serv
opsonin
antibodi
extract
proteaseproduc
target
bacteria
almost
exclus
form
faba
convers
proteasedefici
bacteria
type
bacteria
intact
conclus
result
indic
proteas
activ
neumonia
may
help
bacteria
escap
antibodymedi
opsonophagocytosi
besid
experi
igamedi
opsonophagocytosi
independ
complement
vitamin
e
c
found
increas
cellular
humer
immun
pig
vitamin
e
defici
also
found
predispos
pig
differ
diseas
e
coli
infect
one
among
wean
vitamin
e
statu
pig
often
decreas
critic
low
level
experi
studi
whether
vitamin
c
supplement
would
possibl
feed
strategi
optim
immun
statu
weaner
interact
vitamin
e
c
interest
due
report
spare
action
vitamin
e
synerg
vitamin
piglet
wean
day
age
sow
fed
increas
dietari
vitamin
e
lactat
piglet
follow
week
fed
either
control
diet
diet
supplement
mg
stayc
per
kg
blood
sampl
obtain
weekli
day
day
age
day
one
piglet
per
dietari
treatment
kill
alveolar
macrophag
harvest
vitamin
c
supplement
increas
concentr
igm
serum
piglet
throughout
wean
period
although
vitamin
e
concentr
decreas
increas
age
piglet
concentr
numer
higher
piglet
sow
fed
high
dietari
level
vitamin
e
howev
vitamin
c
supplement
tend
increas
total
concentr
vitamin
e
wean
increas
proport
biolog
activ
isom
vitamin
e
rrr
atocopherol
eicosanoid
synthesi
influenc
vitamin
c
supplement
synthesi
leukotrien
decreas
week
wean
compar
day
harvest
conclus
dietari
vitamin
c
supplement
improv
immun
respons
piglet
wean
whole
blood
stimul
assay
escherichia
coli
endotoxin
establish
measur
capac
dairi
cow
produc
proinflammatori
cytokin
tumour
necrosi
factora
tnfa
ex
vivo
initi
timeand
dosedepend
studi
carri
find
optim
stimul
condit
tnfa
respons
tnfa
respons
peak
h
c
dose
rang
g
e
coli
lipopolysaccharid
lp
ml
whole
blood
found
give
maximum
tnfa
respons
thirtyeight
danishholstein
dairi
cow
investig
tnfa
respons
ex
vivo
periparturi
period
heparinstabil
blood
sampl
collect
seven
time
period
month
week
around
calv
stimul
gml
e
coli
lp
inde
fluctuat
tnfa
respons
occur
time
moreov
mean
tnfa
respons
cow
found
significantli
increas
p
week
close
calv
howev
stabil
physiolog
period
cow
consist
low
tnfa
respons
wherea
other
high
tnfa
respons
current
investig
whether
high
low
tnfa
respond
e
coli
lp
also
exist
dairi
cow
vivo
moreov
import
tnfa
respons
ex
vivo
dairi
cow
suscept
clinic
respons
experiment
e
coli
infect
udder
investig
coelom
cytolyt
factor
ccf
kda
invertebr
pattern
recognit
molecul
isol
coelom
fluid
earthworm
eisenia
foetida
oligochaeta
annelida
ccf
display
number
similar
mammalian
cytokin
tumour
necrosi
factora
tnfa
result
share
n
n
diacetylchitobios
lectinlik
domain
howev
similar
sole
function
base
dna
amino
acid
sequenc
homolog
thu
suggest
form
converg
evolut
particular
lectinlik
domain
tnfa
shown
induc
membran
depolar
variou
mammalian
cell
type
interact
endogen
amiloridesensit
ion
channel
nonreceptormedi
activ
tnfa
report
involv
resorpt
oedema
likewis
lectinlik
domain
ccf
also
induc
membran
depolar
mammalian
cell
show
ccf
appear
abl
induc
oedema
resorpt
alveolar
epitheli
cell
line
lectinlik
domain
lectinlik
domain
ccf
interact
directli
indirectli
endogen
sodium
andor
chlorid
channel
potassium
channel
mammalian
cell
addit
suggest
jnksapk
pathway
involv
ccfinduc
macrophag
activ
result
establish
function
analog
invertebr
pattern
recognit
molecul
mammalian
cytokin
appli
point
view
suggest
possibl
util
ccf
treatment
oedema
releas
svegf
white
blood
cell
platelet
surgeri
stimul
bacteri
antigen
introduct
influenc
surgeri
releas
solubl
vascular
endotheli
growth
factor
svegf
solubl
vascular
endotheli
growth
factor
inhibitori
receptor
unknown
studi
effect
major
minor
surgeri
potenti
variat
svegf
concentr
vivo
bacteri
antigeninduc
releas
svegf
whole
blood
vitro
method
sixtyon
patient
abdomin
diseas
undergo
five
differ
surgic
procedur
includ
blood
sampl
drawn
anaesthet
patient
oper
white
blood
cell
platelet
count
plasma
svegf
determin
elisa
method
whole
blood
blood
sampl
stimul
vitro
bacteriaderiv
antigen
lp
proteina
svegf
level
subsequ
determin
supernat
stimul
isoton
salin
serv
control
assay
neither
svegf
plasma
chang
surgeri
vitro
stimul
blood
sampl
bacteriaderiv
antigen
result
signific
increas
svegf
p
less
pronounc
still
signific
increas
releas
svegf
due
stimul
significantli
higher
oper
nonsignific
wherea
releas
remain
larg
unchang
surgeri
correl
bacteri
antigeninduc
releas
svegf
neutrophil
cell
count
highli
signific
p
correl
svegf
platelet
cell
count
bacteri
antigeninduc
releas
correl
count
neutrophil
platelet
conclus
plasma
svegf
concentr
chang
surgeri
vitro
bacteri
stimul
led
increas
releas
svegf
significantli
amplifi
surgeri
may
relat
number
circul
neutrophil
natur
killer
cell
function
subset
vitro
stimul
special
emphasi
intracellular
ifng
nkcell
cytotox
r
nybo
rix
j
krog
e
hokland
depart
anaesthesiolog
intens
care
aarhu
univers
hospit
institut
medic
microbiolog
immunolog
univers
aarhu
aarhu
denmark
email
rnsr
studmedaudk
materi
method
isol
cryopreserv
human
peripher
blood
mononuclear
cell
pbmc
stimul
stimul
previous
shown
activ
nk
cell
cell
cytotox
measur
flow
cytometri
incub
cell
method
compar
current
standard
releas
assay
cell
treat
bfa
accumul
ifng
stain
surfac
marker
permeabil
stain
intracellular
ifng
flow
cytometri
perform
measur
intracellular
ifng
product
pbmc
especi
nk
cell
result
demonstr
stimul
effect
increas
number
ifngposit
cell
distinct
differ
subset
much
greater
proport
ifngposit
cell
subset
effect
stimul
cytotox
present
relat
ifng
product
cytotox
addit
present
result
assay
appli
porcin
cell
discuss
combin
test
address
nk
cell
function
combin
cytotox
ifng
product
nk
cell
subset
result
demonstr
whether
could
serv
use
tool
describ
nkcell
function
could
valu
clinic
experiment
set
cultur
regulatori
tcell
line
bronchial
mucosa
lymphocyt
play
major
role
mani
immun
respons
last
decad
special
focu
function
effector
cell
import
regulatori
cell
mainten
immunolog
homeostasi
emerg
sarcoidosi
multisystem
granulomat
disord
often
affect
lung
typic
sarcoid
granuloma
consist
epitheloid
cell
macrophag
lymphocyt
mainli
cell
phenotyp
cultur
cell
bronchial
biopsi
patient
sarcoidosi
well
control
high
level
interleukin
demonstr
spontan
aris
popul
high
concentr
cultur
main
differ
cultur
sarcoid
origin
compar
control
much
higher
concentr
inflammatori
cytokin
tnfa
cultur
sarcoid
origin
effect
hyperbar
exposur
human
peripher
blood
mononuclear
cell
special
emphasi
natur
killer
cell
cytotox
subset
materi
method
experiment
physiolog
stress
model
examin
effect
hyperbar
exposur
peripher
blood
mononuclear
cell
pbmc
obtain
venou
blood
drawn
eight
diver
simul
heliox
satur
dive
eight
person
work
normobar
atmospher
outsid
pressur
chamber
serv
control
donor
spontan
cytotox
pbmc
estim
h
assay
use
nksensit
target
cell
pbmc
character
use
flow
cytometri
special
emphasi
nkcell
subset
data
statist
analys
use
multivari
regress
model
stata
p
valu
consid
statist
signific
result
estim
cytotox
increas
significantli
group
diver
control
donor
dive
pdiver
pcontrol
although
cytotox
increas
rel
p
group
diver
compar
group
control
donor
day
discuss
increas
cytotox
pbmc
estim
group
diver
indic
part
cellular
immun
system
affect
extrem
physiolog
condit
induc
initi
phase
present
experiment
hyperbar
setup
increas
cytotox
observ
group
control
donor
could
hypothet
reflect
stress
level
person
work
outsid
pressur
chamber
dive
interact
adhes
molecul
express
vascular
endothelium
first
step
lymphocyt
infiltr
tissu
cutan
mucos
site
transform
growth
factor
tgf
b
import
regul
chronic
inflammatori
diseas
cutan
lymphocyteassoci
antigen
cla
ae
integrin
may
express
unlik
cla
believ
play
role
tissuespecif
home
may
help
retain
cell
within
epitheli
layer
previous
shown
alon
togeth
unknown
cofactor
increas
express
cla
stimul
streptococc
pyrogen
exotoxin
c
spec
increas
express
cell
increas
superantigenstimul
express
cla
cytokin
strongli
inhibit
express
combin
tgfb
complet
abrog
induc
express
convers
suppress
cla
increas
express
find
indic
addit
suppress
develop
inflammatori
respons
may
also
inhibit
migrat
cell
skin
promot
migrat
thu
express
cla
may
antagonist
regul
balanc
cytokin
could
influenc
tcell
migrat
inflammatori
cell
epitheli
tissu
contact
sensit
reaction
immun
cell
prolifer
order
studi
histolog
pictur
prolifer
phase
use
mous
model
contact
sensit
oral
mucosa
skin
also
use
bromodeoxyuridin
brdu
analogu
thymidin
incorpor
nucleu
cell
replic
hapten
oxazolon
oxa
use
sensit
elicit
oral
mucosa
andor
ear
skin
mice
kill
variou
time
elicit
unsensit
anim
also
expos
hapten
control
brdu
mg
kg
anim
inject
ip
h
kill
specimen
oral
mucosa
ear
skin
submandibular
auricular
lymph
node
cut
fix
paraformaldehyd
treat
acid
biotinyl
antibrdu
antibodi
develop
use
abckit
dab
analys
perform
use
leica
light
microscop
comput
program
analysi
oral
mucosa
frequenc
prolifer
cell
increas
observ
period
h
elicit
regardless
site
sensit
prolifer
cell
found
mainli
basal
cell
layer
epithelium
similar
pattern
found
ear
skin
region
lymph
node
demonstr
scatter
prolifer
cell
h
elicit
h
cell
found
frequent
whole
lymph
node
control
anim
exhibit
consider
less
prolifer
cell
time
conclud
prolifer
cell
found
h
elicit
local
haptenexpos
site
oral
mucosa
ear
skin
well
region
lymph
node
endogen
nucleosid
adenosin
releas
excess
inflamm
metabol
stress
gener
known
deliv
tissu
protect
antiinflammatori
effect
adenosin
act
via
four
adenosin
receptor
receptor
predomin
form
cell
adenosin
level
elev
asthmat
lung
adenosin
directli
induc
mast
cell
degranul
bronchoconstrict
patient
instead
role
antiinflammatori
mechan
adenosin
cell
asthma
unclear
aim
studi
receptor
express
peripher
blood
cell
asthmat
healthi
individu
use
flow
cytometr
quantit
realtim
pcr
method
result
unstimul
cell
asthmat
patient
express
significantli
lower
level
p
receptor
protein
level
mean
percentag
cell
posit
ae
sem
ae
n
compar
healthi
individu
ae
n
doubl
stain
express
show
stimul
cell
decreas
express
group
indic
detect
lower
level
unstimul
cell
asthmat
due
preactiv
patient
surprisingli
mrna
express
unstimul
cell
significantli
higher
p
asthmat
n
compar
healthi
control
n
express
correl
serum
total
ige
level
conclus
asthmat
individu
express
less
adenosin
receptor
peripher
cell
higher
mrna
level
instead
may
point
neg
feedback
regul
receptor
express
role
possibl
decreas
adenosinemedi
antiinflammatori
effect
asthma
pathogenesi
requir
studi
tcell
mediat
diseas
chronic
inflammatori
skin
diseas
atop
eczema
ae
affect
almost
popul
mani
countri
today
pathogenesi
ae
fulli
understood
combin
genet
predisposit
environment
factor
like
microorgan
seem
contribut
symptom
yeast
malassezia
sympodiali
part
normal
skin
micro
flora
act
allergen
elicit
specif
ige
tcell
reactiv
patient
ae
recent
identifi
novel
major
sympodiali
allergen
design
mala
kda
sequenc
similar
mitochondri
enzym
manganes
superoxid
dismutas
mnsod
interestingli
mala
high
degre
homolog
human
mnsod
aim
studi
examin
effect
recombin
mala
antigenpres
dendrit
cell
monocytederiv
dendrit
cell
mddc
healthi
blood
donor
cultur
without
mala
differ
time
period
found
matur
marker
costimulatori
molecul
upregul
mddc
expos
mala
h
demonstr
flow
cytometri
furthermor
cocultur
mddc
mala
h
induc
increas
product
inflammatori
cytokin
tnfa
sixfold
detect
cytometr
bead
array
cba
analysi
result
suggest
mala
affect
immun
respons
dc
matur
product
inflammatori
cytokin
potenti
crossreact
human
mnsod
need
explor
exact
role
mala
pathogenesi
ae
assess
clinic
studi
involv
skin
prick
atopi
patch
test
allergenspecif
immunotherapi
sit
commonli
conduct
allergen
extract
adsorb
aluminium
hydroxid
alum
drawback
link
use
alum
format
granuloma
site
inject
led
suggest
novel
allergen
carrier
altern
carrier
mm
carbohydratebas
particl
cbp
mous
allergencoupl
cbp
demonstr
skew
allergenspecif
immun
respons
toward
activ
et
al
immunolog
coupl
recombin
major
cat
allergen
fel
cbp
cbpfel
cyanogenbromid
activ
result
coval
bind
effect
cbpfel
monocytederiv
dendrit
cell
mddc
healthi
human
blood
donor
studi
found
major
mddc
capabl
take
fitclabel
cbpfel
demonstr
flow
cytometri
confoc
laser
scan
microscopi
furthermor
incub
cbpfel
result
upregul
costimulatori
molecul
mddc
observ
fel
cbp
alon
final
cbpfel
induc
fivefold
increas
releas
proinflammatori
cytokin
tumour
necrosi
factor
tnf
fourfold
increas
releas
chemokin
mddc
taken
togeth
effect
cbp
possess
make
interest
novel
allergen
carrier
sit
cystein
proteas
der
dust
mite
genu
dermatophagoid
pteronyssinu
major
type
allergen
hous
dust
mite
hdm
allerg
individu
reactiv
proteas
standard
assay
detect
ige
cur
treatment
atop
allergi
immunotherapi
hdm
extract
complex
mixtur
occasion
result
anaphylact
reaction
novozym
focus
develop
recombin
variant
der
exhibit
lower
risk
igemedi
allerg
reaction
maintain
abil
trigger
proper
thcell
respons
may
provid
safer
altern
specif
hdm
allergi
secret
recombin
form
proder
p
express
saccharamyc
cerevisia
obtain
fusion
proenzym
fungal
signal
peptid
nglycosyl
site
der
mutat
result
deglycosyl
proenzym
molecular
mass
kda
protein
purif
procedur
develop
obtain
nearli
pure
der
protein
follow
determin
concentr
activesitetitr
cystein
proteas
inhibitor
deglycosyl
recombin
proder
p
reveal
immunolog
similar
nativ
der
p
molecul
compar
basophil
histamin
releas
igebind
assay
tcell
prolifer
assay
silico
epitop
map
model
structur
der
five
put
igg
ige
epitop
predict
protein
engin
predict
epitop
remov
one
one
der
screen
hypoallergen
variant
perform
combin
inhal
longact
agonist
laba
inhal
corticosteroid
ic
seem
offer
asthma
control
lower
dose
ic
achiev
ic
alon
fine
map
tcell
surfac
marker
flow
cytometri
offer
detail
statu
individu
inflammatori
respons
frequenc
cell
peripher
blood
ratio
shown
differ
predict
atop
patient
leprosi
correl
phenotyp
phenotyp
stabl
asthmat
requir
fluticason
propion
fp
mg
daili
equival
random
receiv
doubleblind
either
seretid
salmeterol
fluticason
propion
sfc
n
mg
bd
fp
mg
bd
n
asthma
control
base
lung
function
symptom
clinic
visit
everi
week
ic
dose
taper
asthma
exacerb
mg
reach
frequenc
ratio
cell
patient
monitor
week
interv
treatment
taper
frequenc
cell
decreas
p
first
final
visit
wherea
cell
increas
ratio
decreas
p
first
final
visit
patient
receiv
laba
ic
fall
ratio
appear
pronounc
patient
receiv
ic
alon
thu
phenotyp
may
associ
stabl
asthma
wherea
immin
exacerb
may
associ
increas
phenotyp
laba
may
allow
greater
effect
fp
mt
ratio
activ
complement
pathway
lead
product
anaphylatoxin
postul
pathogenesi
asthma
allerg
airway
inflamm
present
studi
undertaken
investig
role
mannanbind
lectin
mbl
initi
lectin
pathway
complement
asthma
allerg
rhiniti
mbl
level
mblinduc
complement
activ
determin
patient
bronchial
asthma
allerg
rhiniti
unrel
agematch
control
indian
origin
mbl
level
activ
correl
percent
eosinophilia
percent
predict
valu
patient
associ
singl
nucleotid
polymorph
snp
exon
intron
mbl
diseas
clinic
marker
mbl
level
mblinduc
complement
activ
analys
use
standard
statist
tool
significantli
higher
mbl
level
activ
observ
patient
bronchial
asthma
allerg
rhiniti
compar
control
identifi
five
snp
two
exon
intron
mbl
novel
snp
significantli
associ
diseas
p
ci
individu
allel
posit
show
increas
mbl
level
activ
diseas
sever
result
suggest
allel
posit
lead
high
mbl
level
complement
activ
may
contribut
sever
bronchial
asthma
allerg
airway
inflamm
serum
resist
borrelia
burgdorferi
strain
belong
b
afzelii
b
burgdorferi
sensu
stricto
genospeci
depend
bind
complement
inhibitor
factor
h
recent
report
factor
h
bind
b
burgdorferi
due
induc
express
sever
approxim
kda
plasmidencod
surfaceexpos
lipoprotein
relat
osp
eg
erpa
erpp
addit
second
class
factor
hbind
protein
approxim
kda
describ
osperel
lipoprotein
dramat
induc
b
burgdorferi
transmiss
tick
vector
mammalian
host
induct
osperel
lipoprotein
mammalian
infect
may
play
key
role
borreli
evas
host
immun
system
goal
present
studi
defin
factor
hbind
region
osperel
protein
use
mutagenesi
peptid
map
surfac
plasmon
reson
analysi
biacor
combin
studi
reveal
ctermin
region
human
mous
factor
h
scr
specif
bind
osperel
lipoprotein
also
found
whose
ctermin
scr
homolog
scr
factor
h
bind
osp
peptid
map
reveal
five
put
region
design
iv
osp
could
directli
interact
factor
h
delet
ctermin
amino
acid
residu
region
v
abolish
abil
bind
factor
h
time
howev
synthet
peptid
correspond
ctermini
osp
erpp
inhibit
factor
h
bind
osp
thu
cterminalbind
region
v
appear
necessari
suffici
factor
h
bind
specif
mutat
strategi
employ
singl
amino
acid
residu
peptid
span
factor
hbind
region
mutat
alanin
observ
lysin
factor
hbind
region
osp
requir
factor
h
bind
combin
data
reveal
key
lysin
residu
osperel
lipoprotein
ionic
interact
crucial
factor
h
interact
furthermor
bind
osp
ctermini
mous
human
factor
h
suggest
borrelia
spirochet
util
analog
complement
resist
mechan
rodent
man
borrelia
garinii
strain
vitro
analys
found
sensit
complement
kill
differ
osp
sequenc
well
express
factor
hbind
protein
may
account
suscept
serum
lysi
role
yada
ail
lipopolysaccharid
serum
resist
yersinia
enterocolitica
serotyp
mannanbind
lectin
mbl
lficolin
hficolin
pattern
recognit
molecul
innat
immun
system
investig
abil
molecul
bind
differ
serotyp
noncapsul
variant
streptococcu
pneumonia
staphylococcu
aureu
found
mbl
bind
noncapsul
aureu
strain
wood
examin
pneumonia
serotyp
lficolin
bind
capsul
pneumonia
serotyp
well
capsul
aureu
serotyp
hficolin
bind
examin
pneumonia
aureu
serotyp
includ
studi
bind
strain
aerococcu
viridan
bound
bacteria
mbl
hficolin
initi
activ
complement
factor
wherea
lficolin
studi
quantit
assay
three
protein
develop
concentr
plasma
sampl
determin
median
valu
estim
mg
mblml
mg
lficolinml
mg
hficolin
ml
respect
absenc
earli
complement
compon
predispos
factor
system
lupu
erythematosu
sle
recent
demonstr
def
mice
igmcontain
immun
complex
igmic
filter
splenic
barrier
margin
zone
macrophag
mzm
result
increas
immun
respons
antigen
within
igmic
could
observ
wildtyp
def
mice
hypothes
splenic
mzm
play
import
role
induct
autoimmun
therefor
analys
cytokin
profil
isol
help
magnet
antibodi
cell
sort
mrna
isol
realtim
pcr
perform
specif
primer
murin
ifng
ifng
ifna
ifna
observ
moder
increas
ifng
mrna
cell
def
mice
compar
wildtyp
cell
surprisingli
concentr
ifna
mrna
six
time
higher
def
mice
preliminari
result
suggest
mrna
cell
def
mice
even
lower
wt
six
hour
follow
iv
applic
mg
abstract
murin
monoclon
igm
antidsdna
antibodi
product
ifng
ifna
mrna
increas
cell
def
wt
mice
sever
refer
describ
increas
level
infa
patient
sle
dendrit
cell
discuss
major
sourc
ifna
observ
slesuscept
mice
demonstr
increas
spontan
ifna
product
splenic
margin
zone
macrophag
could
earli
sign
trigger
develop
sle
support
fact
absenc
predispos
factor
sle
observ
def
anim
display
low
level
ifna
mrna
million
peopl
worldwid
repres
one
lead
caus
liver
cirrhosi
hepatocellular
carcinoma
control
hbv
infect
achiev
mainli
vaccin
hepat
b
surfac
antigen
hbsag
hbsag
contain
nlink
glycosyl
side
recogn
mbla
mblc
cadepend
manner
hbsagmbl
complex
activ
complement
may
thu
affect
humour
immun
investig
role
mbl
humour
respons
hbsag
immunun
mice
lack
mbla
mblc
protein
solubl
hbsag
shown
defici
complement
compon
like
result
decreas
antibodi
respons
howev
mbl
doubl
ko
anim
mount
dramat
increas
humour
respons
prime
mbl
doubl
ko
mount
hbsagspecif
igm
respons
threefold
higher
wt
control
boost
hbsag
total
igg
higher
mbl
ko
wt
control
anim
similar
respons
hbsag
glycosyl
solubl
antigen
eg
invertas
induc
better
humour
respons
mbl
doubl
ko
anim
suggest
mbl
play
import
role
neg
feedback
regul
adapt
immun
reconstitut
experi
rmbl
partial
rescu
ko
phenotyp
propos
clearanc
glycoprotein
antigen
mbl
ko
handl
differ
wt
result
better
stimul
humour
respons
altern
glycoproteinagmblrich
complex
inhibit
bcell
respons
via
put
mbl
receptor
complement
system
import
part
innat
immun
system
activ
complement
proce
three
differ
pathway
converg
gener
enzym
complex
complement
activ
via
lectin
pathway
initi
recognit
molecul
mannanbind
lectin
mbl
ficolin
bind
carbohydr
structur
characterist
microbi
surfac
circul
mbl
ficolin
found
associ
three
structur
relat
mblassoci
serin
proteas
masp
small
nonenzymat
compon
shown
elicit
complement
activ
sequenti
proteolyt
cleavag
upon
bind
complex
microbi
surfac
recent
uncov
polymorph
gene
patient
shown
defici
lectin
pathway
complement
activ
polymorph
result
singl
amino
acid
substitut
ntermin
part
protein
recombin
wildtyp
contain
amino
acid
substitut
question
produc
abil
activ
complement
studi
mutat
profound
impact
function
result
lack
complement
activ
lectin
pathway
elisabas
experi
show
mutat
lead
impair
complement
activ
influenc
bind
mbl
ficolin
defici
lectin
pathway
complement
activ
far
account
lack
function
mbl
mutat
describ
first
defect
describ
affect
activ
mbl
ficolin
treg
cell
balanc
dc
present
gut
mucosa
may
thu
target
modul
gut
microb
includ
ingest
probiot
test
hypothesi
speci
lactic
acid
bacteria
import
member
gut
flora
differenti
activ
dc
larg
panel
human
gutderiv
lactobacillu
bifidobacterium
spp
screen
dcpolar
capac
expos
bone
marrowderiv
murin
dc
lethal
irradi
bacteria
cytokin
cultur
supernat
dcsurfac
matur
marker
analys
substanti
differ
found
among
strain
capac
induc
tumour
necrosi
factor
tnf
differ
less
pronounc
bifidobacteria
tend
weak
tnfa
induc
strong
weak
induc
found
among
strain
lactobacillu
remark
strain
weak
induct
inhibit
tnfa
product
induc
otherwis
strong
cytokineinduc
strain
lactobacillu
casei
product
remain
unalt
select
strain
test
induct
dc
matur
marker
lactobacilli
greatest
capac
induc
effect
upregul
surfac
mhc
class
ii
moreov
l
caseiinduc
upregul
reduc
presenc
weak
l
reuteri
conclus
human
lactobacillu
bifidobacterium
spp
polar
differenti
dc
matur
thu
potenti
exist
capac
gut
dc
modul
accord
composit
gut
flora
includ
ingest
probiot
intestin
micro
flora
indispens
develop
maintain
homeostasi
gutassoci
immun
system
evid
indic
lactic
acid
bacteria
lab
eg
lactobacilli
bifidobacteria
benefici
effect
host
establish
health
effect
includ
increas
gut
matur
antagon
toward
pathogen
immun
modul
object
studi
evalu
immunomodul
properti
rang
lab
human
origin
dendrit
cell
dc
play
pivot
role
balanc
toler
immun
commens
microorgan
vitrogener
immatur
dc
serv
suitabl
model
studi
immunomodul
effect
lab
human
immatur
dc
gener
vitro
monocyt
expos
lethal
uvirradi
lab
effect
variou
speci
lab
dc
direct
contact
evalu
furthermor
matur
pattern
dc
separ
bacteria
epitheli
cell
layer
cell
mimic
intestin
environ
studi
cytokin
secret
tnfa
upregul
matur
surfac
marker
dc
measur
differ
lab
induc
divers
cytokin
respons
strain
strong
tnfa
induc
other
weak
strain
induc
differ
lab
also
differenti
modul
express
dc
although
variat
respons
lab
dc
gener
differ
blood
donor
observ
gener
differ
effect
variou
lab
reveal
experi
dc
cocultur
system
ongo
differ
speci
lab
differenti
affect
dc
matur
sugget
gut
flora
play
pivot
role
polar
immun
respons
natur
killer
nk
cell
cell
nonspecif
immun
system
lyse
alter
selfcel
noncytolyt
subset
nk
cell
may
serv
regulatori
role
secret
cytokin
bacteria
transloc
across
gastrointestin
mucosa
presum
gain
access
nk
cell
consumpt
certain
lactic
acid
bacteria
shown
increas
vivo
nk
cytotox
investig
human
gut
floraderiv
lactobacilli
affect
nk
cell
vitro
measur
prolifer
ifng
product
human
nk
cell
upon
bacteri
stimul
nk
cell
isol
buffi
coat
neg
isol
use
nonnk
lineagespecif
antibodi
magnet
bead
nk
cell
incub
uvinactiv
bacteria
phytohemagglutinin
pha
day
prolifer
assess
incorpor
radioact
thymidin
nkcell
dna
ifng
concentr
measur
elisa
incub
nk
cell
lactobacillu
acidophilu
strain
increas
prolifer
nk
cell
induc
ifng
product
level
compar
pha
stimul
prolif
respons
enhanc
autolog
monocyt
present
probabl
cytokin
secret
monocyt
engulf
bacteria
stimul
nk
cell
contrast
lactobacillu
paracasei
strain
caus
nk
cell
prolifer
presenc
monocyt
result
demonstr
variou
strain
lactobacilli
capac
activ
nk
cell
vitro
monocytedepend
independ
way
henc
encount
nk
cell
lactic
acid
bacteria
affect
nkcell
activ
activ
nk
cell
may
potenti
skew
ongo
subsequ
immun
respons
toward
respons
lactobacilli
nonpathogen
gramposit
inhabit
normal
human
intestin
known
healthpromot
effect
earlier
work
shown
human
monoclon
antibodi
isol
sera
patient
waldenstrom
macroglobulinaemia
possess
innat
antibodi
characterist
bind
lactic
acid
bacteria
accord
immun
network
model
immun
bacteria
could
induc
perturb
immun
system
might
result
product
antilactobacillu
antibodi
human
monoclon
antibodi
like
antiidiotyp
antibodi
studi
balbc
mice
immun
two
dose
bacteria
lactobacillu
acidophilu
complet
incomplet
freund
adjuv
phosphatebuff
salin
pb
respect
seven
day
last
immun
sera
immun
mice
collect
presenc
lactobacillusspecif
determin
elisa
sera
immun
mice
antibodi
specif
bacteria
lactobacillu
acidophilu
shown
concentr
lactobacillusspecif
antibodi
higher
sera
hyperimmun
mice
mice
immun
mg
igm
dj
sera
mice
immun
time
lower
dose
immunogen
mg
per
dose
moreov
antibodi
detect
sera
lactobacillushyperimmun
mice
studi
shown
idiotyp
network
interact
mice
immun
bacteria
lactobacillu
acidophilu
normal
gastrointestin
flora
crucial
matur
acquir
immun
via
effect
antigenpres
cell
apc
investig
two
type
apc
monocyt
dendrit
cell
dc
react
differ
bacteri
strain
typic
commens
intestin
flora
purifi
monocyt
monocytederiv
dc
stimul
uvinactiv
gramposit
lactobacillu
plantarum
bifidobacterium
adolescenti
gramneg
escherichia
coli
veillonella
parvula
bacteri
strain
monocyt
produc
higher
level
tnf
detect
elisa
respons
l
plantarum
e
coli
v
parvula
contrast
dc
secret
high
amount
tnf
respons
e
coli
v
parvula
practic
unrespons
l
plantarum
b
adolescenti
lack
respons
gramposit
strain
correl
lower
surfac
express
tolllik
reseptor
dc
compar
monocyt
surfac
express
dc
undetect
analys
flow
cytometri
block
receptor
decreas
tnf
product
respons
v
parvula
indic
low
express
dc
suffici
mount
inflammatori
respons
gramneg
bacteria
ifng
increas
express
dc
also
potenti
cytokin
respons
gramneg
bacteria
result
indic
monocyt
differenti
dc
abil
respond
differ
commens
bacteria
dramat
chang
therebi
becom
unrespons
probiot
gramposit
bacteria
result
may
import
implic
capac
differ
group
commens
bacteria
regul
mucos
system
immun
probiot
bacteria
eg
lactobacillu
spp
may
improv
diseas
chronic
inflammatori
bowel
diseas
examin
cytokin
product
phenotyp
chang
vitro
stimul
cell
healthi
volunt
use
differ
probiot
strain
method
cell
cultur
colon
biopsi
eight
healthi
volunt
agnholt
kaltoft
exp
clin
immunogenet
dendrit
cell
matur
peripher
blood
mononuclear
cell
tcell
cultur
stimul
autolog
bacteri
sonic
strain
lactobacillu
spp
without
addit
dendrit
cell
cytokin
level
tnfa
ifng
gmcsf
phenotyp
measur
day
result
lactobacillu
spp
induc
higher
product
tnfa
autolog
bacteria
presenc
dendrit
cell
product
cytokin
increas
howev
increas
ifng
tnfa
pronounc
well
autolog
bacteria
well
lactobacillu
spp
addit
dendrit
cell
upregul
express
without
simultan
upregul
upregul
pronounc
stimul
lactobacillu
rhamnosu
gg
compar
autolog
bacteria
lactobacilli
discuss
presenc
dendrit
cell
autolog
bacteria
induc
inflammatori
cytokin
probiot
mainli
induc
regulatori
cytokin
lactobacillu
rhamnosu
gg
induc
regulatori
phenotyp
part
mediat
dendrit
cell
futur
studi
address
whether
shift
phenotyp
repres
differenti
compet
regulatori
cell
clinic
context
cell
might
use
treatment
inflammatori
diseas
protein
microarray
play
key
role
postgenom
era
offer
uniqu
possibl
perform
highthroughput
global
proteom
analysi
chip
print
thousand
protein
probe
eg
antibodi
biolog
sampl
ad
eg
proteom
bind
detect
aim
develop
protein
microarray
base
human
recombin
scfv
antibodi
fragment
global
proteom
analysi
concept
compar
proteom
map
healthi
versu
diseas
sampl
allow
diseasespecif
protein
detect
fact
antibodi
microarray
allow
us
perform
compar
proteom
analysi
sampl
format
speciesindepend
manner
long
proteom
isol
howev
complex
proteom
contain
sever
thousand
differ
protein
problem
design
antibodi
microarray
target
watersolubl
fraction
proteom
end
anticytokin
antibodi
array
develop
human
dendrit
cell
aeactiv
use
model
system
result
show
antibodi
microarray
could
use
examin
cytokin
profil
complex
sampl
furthermor
taken
first
step
toward
compar
result
technolog
protein
gene
level
due
complex
model
proteom
also
examin
possibl
prefraction
proteom
simpl
onestep
procedur
base
size
prior
label
step
detail
sampl
proteom
fraction
two
fraction
use
membran
devic
differ
molecular
weight
cutoff
result
show
fraction
consider
enhanc
assay
sensit
allow
cytokin
pgml
rang
readili
detect
immunomodulatori
effect
heat
shock
protein
immun
dna
construct
base
malari
antigen
fuse
fragment
hsp
prime
type
respons
find
appropri
adjuv
human
vaccin
crucial
heat
shock
protein
hsp
act
adjuv
coadminist
peptid
antigen
given
fusion
protein
howev
potenti
risk
autoimmun
use
complet
molecul
hsp
evolutionari
conserv
overcom
first
evalu
adjuv
effect
two
differ
antigen
lessconserv
fraction
plasmodium
falciparum
compar
whole
molecul
trypanosoma
cruzi
found
exhibit
similar
adjuv
properti
whole
molecul
later
evalu
adjuv
potenti
malari
antigen
chimer
dna
construct
appreci
level
abstract
antibodi
detect
mice
immun
dna
construct
howev
dna
prime
immun
system
subsequ
challeng
correspond
recombin
fusion
protein
elicit
strong
antibodi
respons
contrast
prime
effect
observ
ex
vivo
ifng
product
stimul
hspchimer
fusion
protein
induc
stronger
secret
ifng
vitro
protein
use
result
indic
use
hsp
promis
design
new
vaccin
highthroughput
proteom
antibodybas
microarray
import
probe
surfac
design
analog
dna
microarray
protein
microarray
offer
new
distinct
possibl
perform
sensit
highthroughput
global
proteom
analysi
howev
develop
protein
microarray
technolog
place
high
demand
upon
design
probe
solid
support
analysi
thousand
heterogen
protein
singl
microarray
requir
use
uniform
probe
antibodi
directli
design
protein
microarray
applic
recent
gener
human
recombin
singlechain
fv
antibodi
librari
genet
construct
around
one
framework
ncoderlibrari
contain
clone
singl
framework
antibodi
fragment
sinfab
select
librari
success
appli
probe
microarray
provid
sensit
detect
attomol
mass
spectrometri
zeptomol
rang
fluoresc
howev
choic
framework
critic
shown
select
ncoder
framework
display
excel
function
onchip
stabil
array
dehydr
probe
retain
activ
sever
month
furthermor
address
issu
biocompat
solid
support
immobil
strategi
microarray
setup
inhousedesign
substrat
macropor
silicon
coat
nitrocellulos
display
properti
equal
better
five
commerci
avail
support
use
refer
surfac
also
evalu
differ
coupl
strategi
adsorpt
coval
coupl
diffus
affin
coupl
use
novel
affin
tag
doubl
increas
bind
effici
sinfabmolecul
coat
solid
support
therebi
allow
nonpurifi
probe
directli
appli
mannanbind
lectin
mbl
pathway
part
innat
immun
system
provid
first
line
defenc
infect
mbl
ficolin
circul
complex
mblassoci
serin
proteas
recognit
microorgan
mbl
activ
complement
system
occur
share
five
domain
make
socal
achain
wherea
uniqu
proteas
domain
bchain
identif
assay
masp
present
base
antibodi
achain
new
knowledg
three
masp
share
domain
assay
specif
proteas
domain
construct
one
wish
measur
protein
individu
present
assay
quantifi
total
plasma
serum
sampl
assay
sandwichtyp
assay
use
catch
antibodi
monoclon
antibodi
common
achain
develop
secondari
antibodi
ctermin
part
proteas
domain
use
assay
estim
normal
concentr
protein
well
concentr
patient
also
character
gel
permeat
chromatographi
protein
serum
induc
costimul
ligand
icosl
costimulatori
molecul
relat
b
cell
monocyt
dendrit
cell
endotheli
cell
express
icosl
induc
costimul
ico
interact
icosl
interact
lead
signal
involv
isotyp
switch
develop
immunolog
memori
hitherto
polymorph
gene
describ
aim
studi
reveal
variat
icosl
gene
normal
individu
eight
exon
except
exon
sequenc
flank
intron
healthi
blood
donor
eight
singl
nucleotid
polymorph
snp
two
length
polymorph
found
one
snp
found
code
region
gene
base
involv
locat
exon
caus
conserv
amino
acid
chang
valin
gtt
isoleucin
att
three
individu
heterozyg
ga
exon
polymorph
remain
seven
individu
homozyg
wildtyp
gg
exon
encod
immunoglobulin
variabl
igv
like
domain
molecul
situat
outsid
cell
mean
amino
acid
could
critic
stabil
molecul
could
constitut
part
bind
site
ico
result
form
basi
experi
find
possibl
associ
allel
diseas
caus
immun
dysregul
especi
exon
variant
interest
could
play
role
develop
immunolog
diseas
besid
would
interest
see
whether
exon
allel
express
wildtyp
allel
function
interferonab
ifnab
increasingli
use
antivir
immunomodulatori
therapi
unfortun
bioavail
vari
ifn
speci
mode
administr
ifn
speci
potenti
immunogen
assay
antivir
activ
ifn
antivir
neutral
antibodi
nab
use
time
monitor
patient
ifn
biolog
assay
requir
labori
titrat
make
unsuit
largescal
clinic
use
myxoviru
mxa
resist
gtpbind
protein
specif
induc
treatment
type
ifn
exampl
ifnbinduc
mxa
blood
leucocyt
use
biomark
ifnbtreat
patient
multipl
sclerosi
howev
degre
specif
mxa
regard
unclear
measur
mxa
protein
andor
mrna
yet
suitabl
routin
clinic
use
attempt
find
new
better
report
gene
hope
gene
gene
product
proven
specif
ifna
b
microarray
screen
genechip
affymetrix
carri
use
human
blood
leucocyt
human
lung
carcinoma
cell
line
studi
simultan
express
transcript
exposur
human
recombin
ifna
ifnb
antivir
immunomodulatori
cytokin
result
present
confer
interferonab
ifnab
increasingli
use
antivir
immunomodulatori
therapi
unfortun
bioavail
vari
ifn
speci
mode
administr
ifn
speci
potenti
immunogen
assay
antivir
activ
ifn
antivir
neutral
antibodi
nab
use
time
monitor
patient
ifn
biolog
assay
requir
labori
titrat
make
unsuit
largescal
clinic
use
laboratori
therefor
modifi
antivir
assay
ifn
bioactiv
nab
suitabl
largescal
screen
special
laboratori
readout
surviv
subclon
cell
line
presenc
otherwis
lethal
amount
viru
thu
surviv
increas
presenc
type
ifn
decreas
presenc
nab
ifn
ad
cell
mxa
induc
type
ifn
use
measur
nab
activ
anoth
assay
mxa
level
cell
line
measur
attempt
find
new
better
report
gene
type
ifn
mxa
gene
specif
either
ifna
b
micro
array
screen
carri
use
chip
affymetrix
express
gene
studi
simultan
technolog
result
present
confer
laboratori
develop
databas
system
believ
immedi
interest
gener
scientif
commun
databas
repres
computerbas
replac
laboratori
notebook
use
major
research
laboratori
worldwid
addit
databas
provid
effect
tool
organ
manag
laboratori
inform
level
span
manag
revis
standard
oper
procedur
produc
document
research
activ
keep
track
data
conclus
use
commerci
avail
databas
toolkit
softwar
filemak
pro
develop
relat
databas
solut
manag
laboratori
inform
system
consist
hierarchi
five
interrel
databas
pertain
separ
type
inform
name
overal
project
inform
inform
relat
individu
experi
setup
document
daili
research
activ
gener
data
descript
standard
oper
procedur
like
databas
individu
databas
consist
number
record
compris
set
field
inform
enter
record
certain
field
reserv
specifi
relat
record
record
anoth
databas
higher
level
thu
databas
essenti
five
databas
link
hierarchi
onetomani
relat
organ
inform
folderlik
structur
importantli
databas
system
allow
multipl
user
access
edit
record
simultan
data
enter
one
databas
immedi
becom
access
databas
limit
laboratori
notebook
appar
look
inform
dispers
throughout
one
notebook
possibl
loos
sheet
paper
printout
somewher
often
complic
process
gather
laboratori
data
result
write
grant
applic
research
paper
made
consider
easier
databas
system
thu
databas
solut
present
broadli
attract
research
irrespect
scientif
disciplin
effect
sar
vaccin
like
includ
compon
induc
specif
cytotox
tcell
ctl
respons
specif
respons
govern
hlarestrict
present
sarsderiv
peptid
epitop
exact
knowledg
immun
system
handl
protein
antigen
would
allow
identif
linear
sequenc
directli
genomicproteom
sequenc
inform
latter
recent
establish
caus
coronaviru
sar
cov
isol
fulllength
sequenc
combin
advanc
bioinformat
highthroughput
immunolog
perform
hla
supertyp
genomewid
scan
sarsspecif
cytotox
cell
epitop
scan
includ
nine
human
hla
supertyp
total
cover
major
human
popul
hla
supertyp
select
top
candid
test
biochemicalbind
assay
time
approxim
month
genom
establish
test
major
hla
supertyp
identifi
almost
potenti
vaccin
candid
valid
sar
survivor
use
vaccin
formul
suggest
immunobioinformat
may
becom
fast
valuabl
tool
ration
vaccin
design
rational
major
histocompat
complex
class
mhc
molecul
monitor
protein
content
cell
bind
small
deriv
peptid
present
cytotox
cell
goal
human
mhc
project
predict
bind
strength
given
peptidemhc
complex
predict
allow
design
peptidebas
vaccin
predict
requir
repres
bind
data
mhc
allel
nine
hla
supertyp
describ
genet
construct
protein
product
purif
well
establishmentbind
assay
two
recombin
mhc
supertyp
allel
hlab
hlab
method
use
quikchang
multisit
direct
mutagenesi
kit
stratagen
codonoptim
gene
encod
hlab
hlab
creat
two
mhc
molecul
ferment
purifi
ion
exchang
chromatographi
hydrophob
interact
chromatographi
size
exclus
chromatographi
bind
kd
natur
tcell
epitop
well
predict
peptid
ligand
describ
radioact
immunoassay
ria
enzymelink
immunosorb
assay
elisa
mhc
molecul
biotinyl
express
result
express
mhc
result
multipl
disulfid
bond
isom
separ
hydrophob
interact
chromatographi
use
subsequ
bind
studi
result
determin
kd
variou
peptid
ligand
rang
strong
binder
previous
demonstr
bioinformat
tool
artifici
neural
network
ann
capabl
perform
pathogen
genomeand
hlawid
predict
peptidehla
interact
tool
may
therefor
enabl
fast
ration
approach
epitop
identif
therebi
assist
develop
vaccin
immunotherapi
crucial
step
gener
bioinformat
tool
select
data
repres
event
question
casu
peptidehla
interact
particularli
import
difficult
expens
obtain
data
herein
demonstr
import
select
informationrich
data
develop
comput
method
querybycommitte
perform
global
identif
informationrich
data
unbias
autom
manner
furthermor
demonstr
method
appli
effici
iter
develop
strategi
bioinformat
tool
method
larg
panel
bind
affin
peptid
bind
hla
measur
radioimmunoassay
ria
data
use
develop
multipl
first
gener
ann
form
virtual
committe
committe
use
screen
queri
peptid
ann
agre
lowqbc
disagre
highqbc
hlabind
potenti
seventeen
lowqbc
peptid
highqbc
peptid
synthes
test
highor
lowqbc
data
ad
origin
data
new
highor
lowqbc
second
gener
ann
develop
respect
procedur
repeat
time
highqbcenrich
ann
perform
significantli
better
lowqbcenrich
ann
test
conclus
result
demonstr
highqbcenrich
network
perform
better
lowqbcenrich
network
select
inform
data
develop
peptidemhcbind
predictor
improv
select
data
due
differ
network
train
perform
due
differ
inform
content
highqbc
experi
lowqbc
experi
final
note
strategi
could
use
mani
context
gener
data
difficult
costli
proinflammatori
cytokin
produc
lymphoid
nonlymphoid
cell
critic
role
modul
innat
adapt
immun
primari
function
stimul
ifng
product
stimul
nkcellcytotox
activ
make
cytokin
candid
cancer
immunotherapi
oral
caviti
cytokin
produc
oral
epithelia
carcinoma
cell
relat
tumour
regress
nude
mice
bear
salivari
adenocarcinoma
howev
direct
effect
cytokin
oral
cancer
cell
elucid
project
investig
effect
oral
carcinoma
kb
cell
line
rtpcr
techniqu
kbcell
line
found
express
receptor
indic
oral
carcinoma
line
target
studi
show
recombin
human
inhibit
kbcell
prolifer
concentr
ngml
p
wherea
ldh
releas
cell
treatment
group
control
group
compar
indic
suppress
cell
prolifer
mediat
induct
cell
death
address
hypothesi
found
treatment
induc
apoptot
cell
death
studi
dna
ladder
tunel
assay
addit
express
pattern
cell
deathcontrol
gene
bax
alter
cytokin
find
studi
indic
suppress
kbcell
prolifer
may
attribut
control
cell
cycl
growth
arrest
induct
cell
differenti
data
present
project
could
provid
insight
cancer
cell
directli
respond
cytokin
import
regul
anticanc
mechan
alo
emodin
ae
natur
occur
compound
wide
spectrum
biolog
properti
includ
antimicrobi
vasorelax
immunosuppress
anticanc
action
anthraquinon
induc
apoptosi
sever
tumour
cell
line
special
affin
tumour
neuroectoderm
origin
high
amount
nitric
oxid
releas
activ
macrophag
induc
tumour
cell
death
therefor
explor
capac
ae
modul
nomedi
antitumour
respons
vitro
interestingli
ae
markedli
suppress
releas
macrophag
alon
significantli
potenti
product
cocultur
macrophag
cell
h
cultiv
accordingli
viabil
cell
cocultiv
macrophag
reduc
presenc
ae
moreov
observ
aeimpos
potenti
product
macrophag
close
relat
macrophag
cultur
cell
densiti
accord
data
propos
modul
capac
ae
strongli
depend
intercellular
contact
indic
macrophag
antitumour
respons
compromis
even
potenti
ae
immunotherapi
repres
attract
fourthmod
therapeut
approach
especi
light
shortcom
convent
surgeri
radiat
chemotherapi
manag
metastat
cancer
end
larg
number
peptid
antigen
deriv
taa
appli
immunotherapeut
trial
treatment
variou
malign
eg
cancer
breast
prostat
kidney
addit
haematolog
cancer
case
respons
rate
impress
advers
autoimmun
observ
major
strateg
difficulti
associ
trial
relat
choic
bestsuit
peptid
antigen
vast
major
antigen
describ
thu
far
vital
surviv
growth
tumour
cell
immunoselect
antigenloss
variant
may
therefor
prove
addit
obstacl
clinic
applic
known
peptid
epitop
respect
develop
acquir
antigen
loss
immunotherapi
demonstr
sever
case
obvious
develop
lossvari
tumour
cell
impli
cell
acquir
pronounc
growth
advantag
left
unaffect
treatment
ideal
target
antigen
deriv
protein
requir
surviv
growth
tumour
cell
antigen
characterist
would
inflict
develop
lossvari
tumour
cell
respect
sever
inhibitor
apoptosi
protein
iap
univers
express
among
tumour
play
import
role
tumour
cell
escap
apoptosi
character
spontan
tcell
reactiv
iapderiv
peptid
cancer
patient
iap
survivin
character
peptid
restrict
class
molecul
furthermor
demonstr
survivinspecif
cell
infiltr
metastat
lesion
isol
survivinspecif
ctl
capabl
kill
hlamatch
tumour
cell
survivinderiv
peptid
clinic
trial
continu
work
lab
demonstr
iap
target
spontan
tcell
reactiv
cancer
patient
previous
report
mice
larg
progress
tcell
lymphoma
tumour
dysfunct
antitumour
ctl
activ
occur
associ
accumul
splenic
arginaseproduc
myeloid
suppressor
cell
msc
studi
first
demonstr
presenc
activ
state
msc
depend
tumour
evolut
tumour
regressor
hardli
arginaseproduc
msc
found
amount
arginas
activ
popul
expand
earli
late
progressor
gradual
induct
msc
parallel
increas
suppress
ctl
activ
cytokin
product
upon
analys
molecular
repertoir
msc
vitro
found
besid
wellestablish
marker
altern
activ
myeloid
cell
strong
upregul
ym
two
addit
recent
identifi
marker
evalu
molecular
marker
microarray
analysi
msc
yield
gene
involv
wound
heal
eg
coagul
factor
xiiia
antiinflamm
eg
selenoprotein
p
immunomodul
eg
fat
sugar
metabol
eg
leptin
receptor
note
mani
gene
regul
type
cytokin
therefor
rather
associ
overal
data
provid
new
marker
msc
cancer
establish
activ
state
studi
spa
show
signific
express
normal
mucosa
downregul
crc
absolut
signal
level
nois
threshold
result
interpret
caution
requir
confirm
direct
measuren
protein
result
suggest
major
role
human
collectin
colorect
cancer
